A world without cancer is possible

By supporting ACRF Accelerate you are Backing Brilliant research to help reach a world without cancer.

ACRF Accelerate banner ? ACRF Accelerate banner :

By supporting ACRF Accelerate you are Backing Brilliant research to help reach a world without cancer.

We value your support

We are extremely thankful for the generosity of our philanthropic supporters. We're some of the way towards funding our current projects, but we need your help to reach our target. We invite you to back brilliant.

$ 0

of $2,275,000 raised

We value your support

$ 0

of $2,275,000 raised

What is Accelerate Why ACRF Accelerate Our projects Chat with us

CONTRIBUTE NOW

What is ACRF Accelerate?

ACRF Accelerate is a structured philanthropic initiative led by the Australian Cancer Research Foundation (ACRF). It uses the generous support of people like yourself, willing to make a contribution of at least $5,000, guided by a dedicated relationship manager to back significant life-saving cancer research projects within Australia.

Why Philanthropic giving?

Philanthropic contributions are essential to accelerate progress and improve outcomes for those diagnosed with cancer. By backing brilliant research through ACRF Accelerate, you are funding entire programs of pioneering research.

“We know from cancer researchers that access to better technology and equipment is the key to significantly shifting the dial to improve the prevention, detection and treatment of all cancers.”

– KERRY STRYDOM, ACRF CEO

PLAY VIDEO

Why ACRF Accelerate

What we fund Our unique impact model Your involvement

Researchers tell us that it’s the technology that drives the innovations and breakthroughs in cancer research. Since 1984 we have provided $171 million to 81 projects within 43 organisations through the generosity of all our supporters working together towards a world without cancer.

The ACRF Medical Research Advisory Committee comprises world-renowned scientists and clinicians who ensure only the most deserving of projects are funded. Ultimately this gives you comfort that your donation will result in real, measurable benefits for those diagnosed with or at risk of cancer.

With input from health economics specialists, we have developed a model to articulate the impact of our supported projects. This will help you understand the value of your support and how it contributes socially, scientifically and economically.

HUMAN

Those directly impacted as a result of a cancer diagnosis.

SOCIETAL

Those impacted as a result of the cancer diagnosis of a loved one or someone within their network and, more broadly, society in general.

LEVERAGE

Additional benefits from other organisations as a result of ACRF’s financial involvement.

INTELLECTUAL

New research, creation of jobs in the medical and scientific fields, and contribution to the broader economy.

HUMAN

Those directly impacted as a result of a cancer diagnosis.

SOCIETAL

Those impacted as a result of the cancer diagnosis of a loved one or someone within their network and, more broadly, society in general.

LEVERAGE

Additional benefits from other organisations as a result of ACRF’s financial involvement.

INTELLECTUAL

New research, creation of jobs in the medical and scientific fields, and contribution to the broader economy.

Customised experience and involvement

You can choose how much or how little you want to be involved, and where your money goes – to one or more projects. A minimum contribution of $5,000 is required per project. Or you can share your contribution across all projects through ‘untied funding’.

We’ll keep you informed of progress, but you may want to go a little deeper in your understanding of the research by attending special events and tours. Your dedicated relationship manager will tailor your preferences in line with your wishes.

HUMAN

Those directly impacted as a result of a cancer diagnosis.

SOCIETAL

Those impacted as a result of the cancer diagnosis of a loved one or someone within their network and, more broadly, society in general.

LEVERAGE

Additional benefits from other organisations as a result of ACRF’s financial involvement.

INTELLECTUAL

New research, creation of jobs in the medical and scientific fields, and contribution to the broader economy.

Customised experience and involvement

Our four philanthropic projects for 2022

Immune Therapy Cancer Glycomics Lung Cancer Screening Molecular Theranostics

ACRF Centre for Intravital Imaging of Niches for Cancer Immune Therapy

Realising the full potential of immunotherapy in eradicating cancer.

$ 0

of $750,000 raised

The importance of the microscopes cannot be overstated to understand the role of the immune system in targeting all types of cancer.

Help fund them

Overview

ACRF Centre for Intravital Imaging of Niches for Cancer Immune Therapy.

A world-first project engaging physics and engineering talent to build two Australian-designed microscopes. These will enable researchers to see deeper inside tissues at resolutions currently not possible. Deep biological insights are needed to realise the full potential of cancer immunotherapy to cure all cancers.

Download project details
Projected impact
Human
Greater understanding of the complex interaction between the immune system and cancer cells, matching therapies to tumour-specific characteristics across cancer types.
Leverage
$2.5 million from the Garvan Institute¹ and $300,000 from CCI NSW². The project will be self-sustaining through partner support.
Societal
Reduce the financial burden on caregivers estimated at $33,000 in the first year after diagnosis³.
Intellectual
A core team of 8 Chief Investigators and 17 Associate Investigators will generate $1.42 million⁴ of added value, and an estimated 35 publications.
“By looking in the ‘dark space’ deep inside tumours, we hope to finally answer questions that we have not been able to answer before, revealing crucial insights that will allow us to develop new therapeutic approaches for eradicating cancer in all patients.”

– Professor Tri Phan, Chief Investigator

ACRF International Centre for Cancer Glycomics

Deciphering the cancer-glyco code to develop new life-saving therapies.

$ 0

of $650,000 raised

This unique facility brings world experts in glycomics together for the first time under one roof to combine knowledge to develop precision diagnostics and therapies.

Help fund the facility

Overview

ACRF International Centre for Cancer Glycomics.

This new Glycomics Centre will focus on generating new knowledge that will advance our understanding of cancer glycobiology and enable the translation of this knowledge into the next generation precision diagnostics and therapies to fight cancer, which impacts millions of patients and their families globally.

Download project details
Projected impact
Human
Potential to benefit 7,863 Australians affected by cancer in 2021, where benefit is defined as a 30% reduction in tumour size⁵.

Help to identify early-stage markers in cancers such as ovarian, breast, prostate and colon cancer.
Leverage
Griffith University has pledged an additional $1 million to the project⁶.
Societal
Reduce the burden on caregivers who are at increased risk of health issues, depression and anxiety.

Patients are found to have 1.9x longer progression-free survival, greatly benefiting families and the Australian health system⁷.
Intellectual
A core team of 11 Chief Investigators and 12 scientists and researchers has the potential to generate $516,000⁸ in added value and an estimated 30 publications.
“This research will provide major advances in the early diagnosis of significant cancers, including skin, ovarian and breast cancer. The discovery and development of new drugs to treat these cancers will be another major outcome of this grant.”

– Professor Mark von Itzstein, Chief Investigator

ACRF Lung Cancer Screening Centre of Excellence

Early detection to prevent lung cancer deaths throughout the wider community.

$ 0

of $500,000 raised

By taking world-first mobile lung cancer research on the road, early detection of lung cancer can happen throughout the state.

Help fund early detection

Overview

ACRF Lung Cancer Screening Centre of Excellence.

A Queensland-based, world-first mobile lung cancer research facility focused on early detection research for lung cancer – the leading cause of cancer deaths globally. This pilot program will develop and test a mobile, multi-platform lung cancer detection centre with the aim of reducing health disparities. It will ensure access to rural and remote communities and at-risk populations to ensure equal opportunity for all.

Download project details
Projected impact
Human
Prevent lung cancer deaths of approximately 4,246 Australians per year and reduce lung cancer mortality by 20%.⁹

In the first 10 years, approximately 70% of all screen-detected lung cancer will be diagnosed at an early stage.¹⁰
Leverage
UQ has pledged an additional $120,000 in funding for ACRF LUSCE over five years.¹¹
Societal
Reduce the burden on caregivers who are at increased risk of health issues, depression and anxiety.

Reduce costs associated with premature mortality by 20%, resulting in approximately $1.28 billion in savings.¹²
Intellectual
A core team of 17 Chief Investigators, 24 scientists and researchers have the potential to generate upward of $164,000¹³ in added value, and an estimated 41 publications.
“We have learned from other researchers that trucks can be an alternative way of reaching people who are at risk of lung cancer, to help with screen early detection. This comes from important work in the UK, where trucks have been shown to improve the participation rate, and to allow people to be diagnosed and cured of lung cancer early.”

– Professor Kwun Fong, Chief Investigator

ACRF Molecular Theranostics Laboratory

An emerging field of cancer research with the potential to revolutionise cancer treatment.

$ 0

of $750,000 raised

This laboratory will be at the forefront of theranostics, providing a revolution in cancer treatment.

Help fund FAPi

Overview

ACRF Molecular Theranostics Laboratory.

The new ACRF Molecular Theranostics Laboratory will house world-leading research into the use of theranostics to treat cancer. A form of personalised cancer treatment for the patient, the term ‘theranostics’ refers to a combined therapy and diagnostics approach. An exciting and emerging field, theranostics has the potential to revolutionise cancer treatment, employing tumour markers to deliver a therapeutic isotope (radioactive drug) directly to tumour cells to kill them.

Download project details
Projected impact
Human
Improved prognosis of 12,595 Australians at risk of dying from solid tumours each year.¹⁴

Detection of liver cirrhosis in in approximately 69,000 Australians and the potential to prevent early death in over 2,100 Australians.¹⁵
Leverage
The Centenary Institute has pledged an additional $300,000, and the Cancer Institute New South Wales has pledged another $300,000.¹⁶
Societal
Reduce cancer costs by approximately $174 million each year across 12,000 patients.

Reduce the burden on caregivers who experience an estimated 23% reduction in work productivity, costing employers approximately $12,784 a year.¹⁷
Intellectual
A core team of 6 Chief Investigators, 13 scientists and researchers has the potential to generate $409,000 in added value, and an estimated 30.5 publications.¹⁸
“Researchers at the ACRF Molecular Theranostics Laboratory have devised a theranostic approach that we hope will work against all types of solid tumours. It has an inbuilt self-amplifying mechanism of action, meaning that it should become substantially more effective with each administration.”

– Professor Philip Hogg, Chief Investigator

ACRF Centre for Intravital Imaging of Niches for Cancer Immune Therapy

Realising the full potential of immunotherapy in eradicating cancer.

$ 0

of $750,000 raised

The importance of the microscopes cannot be overstated to understand the role of the immune system in targeting all types of cancer.

Help fund them

Overview

ACRF Centre for Intravital Imaging of Niches for Cancer Immune Therapy.

A world-first project engaging physics and engineering talent to build two Australian-designed microscopes. These will enable researchers to see deeper inside tissues at resolutions currently not possible. Deep biological insights are needed to realise the full potential of cancer immunotherapy to cure all cancers.

Download project details
Projected impact
Human
Greater understanding of the complex interaction between the immune system and cancer cells, matching therapies to tumour-specific characteristics across cancer types.
Leverage
$2.5 million from the Garvan Institute¹ and $300,000 from CCI NSW². The project will be self-sustaining through partner support.
Societal
Reduce the financial burden on caregivers estimated at $33,000 in the first year after diagnosis³.
Intellectual
A core team of 8 Chief Investigators and 17 Associate Investigators will generate $1.42 million⁴ of added value, and an estimated 35 publications.
“By looking in the ‘dark space’ deep inside tumours, we hope to finally answer questions that we have not been able to answer before, revealing crucial insights that will allow us to develop new therapeutic approaches for eradicating cancer in all patients.”

– Professor Tri Phan, Chief Investigator

ACRF International Centre for Cancer Glycomics

Deciphering the cancer-glyco code to develop new life-saving therapies.

$ 0

of $650,000 raised

This unique facility brings world experts in glycomics together for the first time under one roof to combine knowledge to develop precision diagnostics and therapies.

Help fund the facility

Overview

ACRF International Centre for Cancer Glycomics.

This new Glycomics Centre will focus on generating new knowledge that will advance our understanding of cancer glycobiology and enable the translation of this knowledge into the next generation precision diagnostics and therapies to fight cancer, which impacts millions of patients and their families globally.

Download project details
Projected impact
Human
Potential to benefit 7,863 Australians affected by cancer in 2021, where benefit is defined as a 30% reduction in tumour size⁵.

Help to identify early-stage markers in cancers such as ovarian, breast, prostate and colon cancer.
Leverage
Griffith University has pledged an additional $1 million to the project⁶.
Societal
Reduce the burden on caregivers who are at increased risk of health issues, depression and anxiety.

Patients are found to have 1.9x longer progression-free survival, greatly benefiting families and the Australian health system⁷.
Intellectual
A core team of 11 Chief Investigators and 12 scientists and researchers has the potential to generate $516,000⁸ in added value and an estimated 30 publications.
“This research will provide major advances in the early diagnosis of significant cancers, including skin, ovarian and breast cancer. The discovery and development of new drugs to treat these cancers will be another major outcome of this grant.”

– Professor Mark von Itzstein, Chief Investigator

ACRF Lung Cancer Screening Centre of Excellence

Early detection to prevent lung cancer deaths throughout the wider community.

$ 0

of $500,000 raised

By taking world-first mobile lung cancer research on the road, early detection of lung cancer can happen throughout the state.

Help fund early detection

Overview

ACRF Lung Cancer Screening Centre of Excellence.

A Queensland-based, world-first mobile lung cancer research facility focused on early detection research for lung cancer – the leading cause of cancer deaths globally. This pilot program will develop and test a mobile, multi-platform lung cancer detection centre with the aim of reducing health disparities. It will ensure access to rural and remote communities and at-risk populations to ensure equal opportunity for all.

Download project details
Projected impact
Human
Prevent lung cancer deaths of approximately 4,246 Australians per year and reduce lung cancer mortality by 20%.⁹

In the first 10 years, approximately 70% of all screen-detected lung cancer will be diagnosed at an early stage.¹⁰
Leverage
UQ has pledged an additional $120,000 in funding for ACRF LUSCE over five years.¹¹
Societal
Reduce the burden on caregivers who are at increased risk of health issues, depression and anxiety.

Reduce costs associated with premature mortality by 20%, resulting in approximately $1.28 billion in savings.¹²
Intellectual
A core team of 17 Chief Investigators, 24 scientists and researchers have the potential to generate upward of $164,000¹³ in added value, and an estimated 41 publications.
“We have learned from other researchers that trucks can be an alternative way of reaching people who are at risk of lung cancer, to help with screen early detection. This comes from important work in the UK, where trucks have been shown to improve the participation rate, and to allow people to be diagnosed and cured of lung cancer early.”

– Professor Kwun Fong, Chief Investigator

ACRF Molecular Theranostics Laboratory

An emerging field of cancer research with the potential to revolutionise cancer treatment.

$ 0

of $750,000 raised

This laboratory will be at the forefront of theranostics, providing a revolution in cancer treatment.

Help fund FAPi

Overview

ACRF Molecular Theranostics Laboratory.

The new ACRF Molecular Theranostics Laboratory will house world-leading research into the use of theranostics to treat cancer. A form of personalised cancer treatment for the patient, the term ‘theranostics’ refers to a combined therapy and diagnostics approach. An exciting and emerging field, theranostics has the potential to revolutionise cancer treatment, employing tumour markers to deliver a therapeutic isotope (radioactive drug) directly to tumour cells to kill them.

Download project details
Projected impact
Human
Improved prognosis of 12,595 Australians at risk of dying from solid tumours each year.¹⁴

Detection of liver cirrhosis in in approximately 69,000 Australians and the potential to prevent early death in over 2,100 Australians.¹⁵
Leverage
The Centenary Institute has pledged an additional $300,000, and the Cancer Institute New South Wales has pledged another $300,000.¹⁶
Societal
Reduce cancer costs by approximately $174 million each year across 12,000 patients.

Reduce the burden on caregivers who experience an estimated 23% reduction in work productivity, costing employers approximately $12,784 a year.¹⁷
Intellectual
A core team of 6 Chief Investigators, 13 scientists and researchers has the potential to generate $409,000 in added value, and an estimated 30.5 publications.¹⁸
“Researchers at the ACRF Molecular Theranostics Laboratory have devised a theranostic approach that we hope will work against all types of solid tumours. It has an inbuilt self-amplifying mechanism of action, meaning that it should become substantially more effective with each administration.”

– Professor Philip Hogg, Chief Investigator

“We chose ACRF specifically as it is one of the Sunrise Foundation’s goals to provide philanthropic support to agencies that ensure monies received are directed efficiently where they are needed the most – i.e. with the least amount of cost. Supporting the dedicated pursuit of knowledge through research is one small way that we feel we can help to make a difference.”

– Sunrise Foundation Family

“A number of years ago, I was looking for a worthy charity to donate money to. I looked at a number of charities and ACRF stood out in the crowd due to the way they engage with their donors. I have supported them ever since. I believe that scientists, doctors and researchers benefit society in an immeasurable way and I see we can create real change through research.”

– Andrew Czarnecki, ACRF Supporter

“With Accelerate you get to see what the aim of the particular research is and where it is going to, you get to see the people behind it, it tells you the impact it has on an individual, the impact it has on families; all the things you don’t really take into consideration when someone is suffering a cancer.”

– Gordon Jackson, ACRF Supporter

Victoria Bonsey

ACRF Philanthropy Manager

Thank you for your interest in backing brilliant cancer research. I’m here to help you make informed decisions in helping achieve a world without cancer. By listening to your wishes and motivations, I can direct your attention to the most worthwhile research projects aligned with your own objectives.